Literature DB >> 21789155

Balancing the efficacy and toxicity of chemotherapy in colorectal cancer.

Michael S Braun1, Matthew T Seymour.   

Abstract

As the therapeutic options for the treatment of colorectal cancer have expanded over the past 20 years, so has the complexity of decision making. The goals of treatment in the palliative, adjuvant and neoadjuvant settings vary and it is not only the efficacy of drugs that influence treatment decisions. Age, performance status, the presence of significant comorbidities and the different treatment regimens and strategies provide medical oncologists with an array of options to attempt to maximize patients' quality of life and longevity.

Entities:  

Keywords:  colorectal cancer; combination chemotherapy; fluorouracil; irinotecan; oxaliplatin; performance status; staged chemotherapy; toxicity; treatment breaks

Year:  2011        PMID： 21789155      PMCID： PMC3126034          DOI： 10.1177/1758834010388342

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  43 in total

1.  Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.

Authors:  J A Ledermann; P Leonard; M Seymour
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

2.  Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients.

Authors:  Halfdan Sorbye; Per Pfeiffer; Nina Cavalli-Björkman; Camilla Qvortrup; Mari H Holsen; Tore Wentzel-Larsen; Bengt Glimelius
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

3.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Authors:  E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

4.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

Authors:  A de Gramont; J F Bosset; C Milan; P Rougier; O Bouché; P L Etienne; F Morvan; C Louvet; T Guillot; E François; L Bedenne
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

Authors:  P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

6.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates.

Authors:  G Folprecht; A Grothey; S Alberts; H-R Raab; C-H Köhne
Journal:  Ann Oncol       Date:  2005-05-03       Impact factor: 32.976

7.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

8.  Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer.

Authors:  Daniel J Sargent; Claus Henning Köhne; Hanna Kelly Sanoff; Brian M Bot; Matthew T Seymour; Aimery de Gramont; Ranier Porschen; Leonard B Saltz; Philippe Rougier; Christopher Tournigand; Jean-Yves Douillard; Richard J Stephens; Axel Grothey; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

9.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Authors:  Jolien Tol; Miriam Koopman; Annemieke Cats; Cees J Rodenburg; Geert J M Creemers; Jolanda G Schrama; Frans L G Erdkamp; Allert H Vos; Cees J van Groeningen; Harm A M Sinnige; Dirk J Richel; Emile E Voest; Jeroen R Dijkstra; Marianne E Vink-Börger; Ninja F Antonini; Linda Mol; Johan H J M van Krieken; Otilia Dalesio; Cornelis J A Punt
Journal:  N Engl J Med       Date:  2009-02-05       Impact factor: 91.245

10.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

Authors:  Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321
View more
  34 in total

1.  Effect of the polyphenol composition BP-C3 on haematological and intestinal indicators of 5-fluorouracil toxicity in mice.

Authors:  Andrey V Panchenko; Elena I Fedoros; Sergey E Pigarev; Mikhail A Maydin; Ekaterina A Gubareva; Maria N Yurova; Galina S Kireeva; Galina P Lanskikh; Margarita L Tyndyk; Vladimir N Anisimov
Journal:  Exp Ther Med       Date:  2018-01-22       Impact factor: 2.447

2.  Engineering bacteria for cancer therapy.

Authors:  Tetsuhiro Harimoto; Tal Danino
Journal:  Emerg Top Life Sci       Date:  2019-11-11

3.  Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.

Authors:  Ilufredo Y Tantoy; Anand Dhruva; Janine Cataldo; Alan Venook; Bruce A Cooper; Steven M Paul; Jon D Levine; Yvette P Conley; Frances Cartwright; Kathryn Lee; Fay Wright; Christine Miaskowski
Journal:  J Gastrointest Oncol       Date:  2017-02

Review 4.  Indole-3-carbinol induces tumor cell death: function follows form.

Authors:  Bryant W Megna; Patrick R Carney; Manabu Nukaya; Pete Geiger; Gregory D Kennedy
Journal:  J Surg Res       Date:  2016-04-22       Impact factor: 2.192

Review 5.  Which strategy after first-line therapy in advanced colorectal cancer?

Authors:  Coinu Andrea; Petrelli Fausto; Borgonovo Karen Francesca; Cabiddu Mary; Ghilardi Mara; Lonati Veronica; Barni Sandro
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

6.  The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.

Authors:  Grant R Williams; Allison M Deal; Shlomit Strulov Shachar; Christine M Walko; Jai N Patel; Bert O'Neil; Howard L McLeod; Marc S Weinberg; Seul Ki Choi; Hyman B Muss; Hanna K Sanoff
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-20       Impact factor: 3.333

7.  Differential effects of grape seed extract against human colorectal cancer cell lines: the intricate role of death receptors and mitochondria.

Authors:  Molly Derry; Komal Raina; Rajesh Agarwal; Chapla Agarwal
Journal:  Cancer Lett       Date:  2012-12-23       Impact factor: 8.679

8.  Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

Authors:  Greg Yothers; Michael J O'Connell; Mark Lee; Margarita Lopatin; Kim M Clark-Langone; Carl Millward; Soonmyung Paik; Saima Sharif; Steven Shak; Norman Wolmark
Journal:  J Clin Oncol       Date:  2013-11-12       Impact factor: 44.544

Review 9.  Oral versus intravenous fluoropyrimidines for colorectal cancer.

Authors:  Fiona Chionh; David Lau; Yvonne Yeung; Timothy Price; Niall Tebbutt
Journal:  Cochrane Database Syst Rev       Date:  2017-07-28

10.  Design, Synthesis, Characterization, and Crystal Structure Studies of Nrf2 Modulators for Inhibiting Cancer Cell Growth In Vitro and In Vivo.

Authors:  Prathima Chikkegowda; Baburajeev C Pookunoth; Venugopal R Bovilla; Prashanthkumar M Veeresh; Zonunsiami Leihang; Thippeswamy Thippeswamy; Mahesh A Padukudru; Basavanagowdappa Hathur; Rangappa S Kanchugarakoppal; SubbaRao V Madhunapantula
Journal:  ACS Omega       Date:  2021-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.